These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11812565)

  • 21. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
    Schoedel KA; Hoffmann EB; Rao Y; Sellers EM; Tyndale RF
    Pharmacogenetics; 2004 Sep; 14(9):615-26. PubMed ID: 15475735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP2A6: a human coumarin 7-hydroxylase.
    Pelkonen O; Rautio A; Raunio H; Pasanen M
    Toxicology; 2000 Apr; 144(1-3):139-47. PubMed ID: 10781881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.
    Malaiyandi V; Sellers EM; Tyndale RF
    Clin Pharmacol Ther; 2005 Mar; 77(3):145-58. PubMed ID: 15735609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.
    Oscarson M; McLellan RA; Gullstén H; Agúndez JA; Benítez J; Rautio A; Raunio H; Pelkonen O; Ingelman-Sundberg M
    FEBS Lett; 1999 Oct; 460(2):321-7. PubMed ID: 10544257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP2A6 polymorphism, nicotine, and environmental nitrosamines.
    Idle JR
    Lancet; 1999 Jun; 353(9169):2073. PubMed ID: 10376647
    [No Abstract]   [Full Text] [Related]  

  • 26. CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians.
    Inoue K; Yamazaki H; Shimada T
    Arch Toxicol; 2000 Jan; 73(10-11):532-9. PubMed ID: 10663384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolism and disposition kinetics of nicotine.
    Hukkanen J; Jacob P; Benowitz NL
    Pharmacol Rev; 2005 Mar; 57(1):79-115. PubMed ID: 15734728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation.
    Kubota T; Nakajima-Taniguchi C; Fukuda T; Funamoto M; Maeda M; Tange E; Ueki R; Kawashima K; Hara H; Fujio Y; Azuma J
    Pharmacogenomics J; 2006; 6(2):115-9. PubMed ID: 16402086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
    Malaiyandi V; Goodz SD; Sellers EM; Tyndale RF
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1812-9. PubMed ID: 17035386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration.
    Schoedel KA; Sellers EM; Palmour R; Tyndale RF
    Mol Pharmacol; 2003 Jan; 63(1):96-104. PubMed ID: 12488541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations.
    Shimada T; Yamazaki H; Guengerich FP
    Xenobiotica; 1996 Apr; 26(4):395-403. PubMed ID: 9173680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of human cytochrome P4502A6 in C-oxidation of nicotine.
    Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
    Drug Metab Dispos; 1996 Nov; 24(11):1212-7. PubMed ID: 8937855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.
    Nakajima M; Yokoi T
    Drug Metab Pharmacokinet; 2005 Aug; 20(4):227-35. PubMed ID: 16141602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nicotine metabolism and elimination kinetics in newborns.
    Dempsey D; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 2000 May; 67(5):458-65. PubMed ID: 10824624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
    Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF
    Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.
    Al Koudsi N; Mwenifumbo JC; Sellers EM; Benowitz NL; Swan GE; Tyndale RF
    Eur J Clin Pharmacol; 2006 Jun; 62(6):481-4. PubMed ID: 16758265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
    Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
    Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking.
    Sellers EM; Kaplan HL; Tyndale RF
    Clin Pharmacol Ther; 2000 Jul; 68(1):35-43. PubMed ID: 10945314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of specificity and activity in mammalian cytochrome P-450.
    Lindberg RL; Negishi M
    Methods Enzymol; 1991; 202():741-52. PubMed ID: 1784197
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic variation of CYP2A6, smoking, and risk of cancer.
    London SJ; Idle JR; Daly AK; Coetzee GA
    Lancet; 1999 Mar; 353(9156):898-9. PubMed ID: 10093988
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.